Insys Therapeutics to assess strategic alternatives for opioid portfolio

INSYS Therapeutics announced that it has commenced a process to review strategic alternatives for its portfolio of opioid-related assets, including Subsyr fentanyl sublingual spray, which has been commercially available in the United States since 2012, as well as formulations of buprenorphine and the combination of buprenorphine/naloxone.
https://thefly.com/landingPageNews.php?id=2817811